Meeting
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
Authors
Ilya Tsimafeyeu
Kidney Cancer Research Bureau, Moscow, Russia
Ilya Tsimafeyeu , Natalia N. Petenko , Anton Snegovoy , Sergey Varlamov , Lev V. Demidov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 520)
DOI
10.1200/jco.2014.32.4_suppl.520
Abstract #
520
Poster Bd #
H13
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan
Poster
2016 ASCO Annual Meeting
Association of high cost sharing and target therapy initiation among Medicare patients with metastatic renal cell carcinoma.
First Author: Pengxiang Li
Poster
2015 Genitourinary Cancers Symposium
Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
First Author: Daniel Yick Chin Heng
Poster
2014 ASCO Quality Care Symposium
Reporting on quality indicators in renal cell carcinoma: Proportion of metastatic patients who initially commence on full-dose targeted therapy.
First Author: Lori Wood